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Psychosis is a severe mental illness which is characterized by distortion of reality (delusion and 
hallucination); disorganized thought or language; and markedly abnormal psychomotor behaviour (such 
as stupor and mutism).   Psychotic disorders remain a vast public health burden and are associated with 
significant disability and morbidity, high societal costs, as well as mortality.(McGrath et al., 2008) Well 
known risk factors for psychosis include family history, gender, abnormal foetal development, 
neurodegenerative diseases, and socioeconomic factors.(Benros et al., 2011; Heckers, 2009) Though these 
factors significantly elevate the risk for psychosis, they do not fully explain its pathogenesis.  
Psychosis is a preventable mental illness and therefore there is a need to evaluate putative risk factors 
that may contribute to its development. Gamma-glutamyltransferase (GGT), a known marker of liver 
injury, has been implicated in the development of a vast array of chronic disease outcomes;(Kunutsor, 
2016) via pathways related to inflammation and oxidative stress. Emerging evidence also suggests that 
inflammatory processes may be involved in the etiopathogenesis of psychosis.(Feigenson et al., 2014) We 
therefore hypothesized that GGT will be linked to the development of psychosis. In this context, we 
aimed to assess the association of GGT with risk of psychosis, using a population-based cohort of 2,341 
men free from any apparent mental illness at baseline from eastern Finland.  
Study population comprised a representative sample of middle-aged men aged 42-61 years recruited 
into the Finnish Kuopio Ischemic Heart Disease (KIHD) risk factor study.(Salonen et al., 1992)  The 
Research Ethics Committee of the University of Eastern Finland approved the study, and each participant 
gave written informed consent. Men on antipsychotic medication (n=52) were excluded at baseline. 
Serum GGT activity was measured at baseline using the kinetic method (Thermo Fisher Scientific, 
Vantaa, Finland) with repeat measurements performed several years apart in a random subset of 
participants. Data on hospitalization due to a psychotic disorder were ascertained by linkage to the 
National Hospital Discharge Register. Diagnoses of psychotic disorders were made by qualified 
psychiatrists according to ICD-8 (290-299), ICD-9 (290-299), and ICD-10 (F00-F09 and F20-F29) codes. 
Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox proportional hazard 
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models. All statistical analyses were conducted using Stata version 14 (Stata Corp, College Station, 
Texas). 
The mean age [standard deviation (SD)] of participants at baseline was 53 (5) years. The median 
(interquartile range) baseline GGT activity was 20 (15-33) U/L. During a median follow-up of 24.7 years, 
230 hospital diagnosed psychotic disorders were recorded. In analysis adjusted for conventional risk 
factors (age, body mass index, smoking status, history of diabetes, prevalent history of coronary heart 
disease, years of education, total cholesterol, and alcohol consumption), there was a log-linear 
association between GGT and risk of psychosis (Figure). The age-adjusted HR for psychosis per 1 SD 
increase in GGT was 1.52 (95% CI: 1.34 to 1.73), which was minimally attenuated to 1.44 (95% CI: 1.25 
to 1.66) on further adjustment for established risk factors. The association remained consistent on 
additional adjustment for potential confounders 1.43 (95% CI: 1.24 to 1.65). After correction for within-
person variability in GGT values, the similarly adjusted HRs were 1.84 (95% CI: 1.53 to 2.21), 1.70 (95% 
CI: 1.39 to 2.08), and 1.67 (95% CI: 1.36 to 2.06) respectively (Table).  
In this population of approximately healthy middle-aged Finnish men, our results show a positive and 
independent association between GGT and future risk of psychosis, which was consistent with a graded 
dose-response pattern. Over the last few decades, emerging evidence suggests that chronic inflammatory 
processes (Benros et al., 2011; Feigenson et al., 2014)  as well as oxidative stress (Owe-Larsson et al., 
2011) may be involved in the pathogenesis of psychotic disorders. Whether GGT has a direct role in the 
pathogenesis or may just be a marker of underlying pathology, is not clear. However, given that GGT has 
been suggested to contribute to the development of chronic disease outcomes mainly via inflammation 
(Anderson et al., 1982) and oxidative stress;(Lee et al., 2004) we postulate that these same pathways 
might underlie the current findings.  
This is the first prospective evaluation of the association between GGT and risk of psychosis using a 
large-scale population-based prospective general cohort study comprising participants free from mental 
illness at baseline. The study findings however need to be interpreted in light of the following limitations: 
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(i) the study sample comprised only men, therefore the results cannot be generalized to women; and (ii) 
our analyses focused on all types of psychotic disorders, since data on specific conditions such as 
schizophrenia and severe depression were not available. 
In conclusion, GGT is associated with future risk of psychosis in a graded dose-response pattern in 
middle-aged Caucasian men. Serum GGT may have relevance for the prevention of psychosis; however, 
further research is needed to elucidate the mechanistic pathways underlying this association. 
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Figure legend 
Figure. Hazard ratios for psychosis, by quartiles of baseline values of gamma-glutamyltransferase 
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A, adjusted for age; B, adjusted for age, plus body mass index, smoking status, history of diabetes, 
prevalent coronary heart disease, years of education, total cholesterol, and alcohol consumption 
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Table. Association of serum GGT and psychosis 
Serum GGT 
(U/L) 
Events/ 
Total 
Model 1  Model 2  Model 3  
  HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
Baseline GGT 
Per 1 SD 
increase 
230 / 2,341 1.52 (1.34 to 1.73) < 0.001 1.44 (1.25 to 1.66) < 0.001 1.43 (1.24 to 1.65) < 0.001 
Q1 (5-15) 58 / 701 ref  ref  ref  
Q2 (16-20) 47 / 490 1.26 (0.86 to 1.86) 0.235 1.20 (0.81 to 1.77) 0.358 1.16 (0.79 to 1.72) 0.450 
Q3 (21-33) 57 / 604 1.32 (0.92 to 1.91) 0.134 1.20 (0.82 to 1.75) 0.338 1.16 (0.79 to 1.69) 0.457 
Q4 (≥ 34) 68 / 546 2.23 (1.57 to 3.17) < 0.001 1.83 (1.24 to 2.69) 0.002 1.76 (1.19 to 2.60) 0.005 
Usual GGT* 
Per 1 SD 
increase 
230 / 2,341 1.84 (1.53 to 2.21) < 0.001 1.70 (1.39 to 2.08) < 0.001 1.67 (1.36 to 2.06) < 0.001 
Q1 (5-15) 58 / 701 ref  ref  ref  
Q2 (16-20) 47 / 490 1.40 (0.80 to 2.45) 0.235 1.30 (0.74 to 2.29) 0.358 1.24 (0.70 to 2.20) 0.450 
Q3 (21-33) 57 / 604 1.50 (0.88 to 2.55) 0.134 1.31 (0.76 to 2.26) 0.338 1.23 (0.71 to 2.14) 0.457 
Q4 (≥ 34) 68 / 546 3.20 (1.93 to 5.34) < 0.001 2.40 (1.37 to 4.19) 0.002 2.26 (1.28 to 3.99) 0.005 
 
CI, confidence interval; GGT, gamma-glutamyltransferase; HR, hazard ratio; ref, reference; Q, quartile; SD, standard deviation; 
*, indicates correction for within-person variability in values of GGT, that is, the extent to which an individual’s GGT 
measurements vary around a long-term average value (“usual GGT values”); 1 standard deviation higher loge GGT is 
approximately equivalent to two-fold higher GGT values. 
Model 1: Adjusted for age  
Model 2: Model 1 plus body mass index, smoking status, history of diabetes, prevalent coronary heart disease, years of education, 
total cholesterol, and alcohol consumption 
Model 3: Model 2 plus total energy intake, socioeconomic status, physical activity, and C-reactive protein 
 
 
 
 
 
